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Objective:We have observed that some patients with isolated popliteal artery occlusions (PAOs) harbor varying degrees of
organized clot, as suggested by the rapidity with which these occlusions are traversed with the Glidewire. We
hypothesized that debulking such PAOs by using rheolytic thrombectomy without adjunctive thrombolysis before
percutaneous transluminal angioplasty and selective stenting (PTA/S) is safe and enables single-session treatment with
minimal risk of embolization.
Methods: Between February 2004 and January 2007, 16 male patients (mean age, 68.9  11.1 years; range, 54-84 years)
presenting with disabling claudication (n  1), rest pain (n  5), and tissue loss (n  10; mean duration, 11  8 weeks;
range, 4-26 weeks) were prospectively followed up after rheolytic thrombectomy and angioplasty and selective stenting
of their PAO.
Results: The mean occlusion length was 11.6  4.5 cm. After rheolytic thrombectomy, the occlusions were converted to
long stenoses (mean length of 7.6 3.6 cm). Self-expanding stents were used in 10 of 16 (mean length of 8.3 4.4 cm).
Additional recanalizations of occlusions of the iliac artery and proximal superficial femoral artery were performed before
popliteal artery recanalizations in two patients. Ankle-brachial indexes increased from 0.27  0.22 to 0.94  0.13. No
case of distal embolization was observed. Adjuvant thrombolysis was used in only one case to improve runoff. Inline flow
to the foot was achieved in 15 of 16 cases. Three occlusions occurred at 3, 6, and 20 months after surgery (mean
follow-up, 15.7 10.0 months), and two patients underwent successful thrombolysis. The third patient refused further
intervention and remains a claudicant. One-year primary and secondary patency rates were 84% and 92%, respectively.
Two limb losses occurred at 7 and 9 months as a result of recurrent foot infection in patients with diabetes, both with
patent popliteal arteries (1-year limb salvage rate, 83%).
Conclusions: We advocate debulking isolated subacute PAOs with rheolytic thrombectomy when they are easily crossed,
because this enables recanalization of these lesions in a single setting, thus obviating the additional need for thrombolysis
in most cases, with seemingly minimal risk of distal embolization. This simple approach is effective and widely available.
(J Vasc Surg 2007;46:717-23.)Successful recanalization of subacute (2 weeks and
3 months) and chronic occlusions with thrombolytic
therapy—usually in combination with angioplasty and
stenting—in various arterial beds has increased awareness of
the presence of varying degrees of organized clot compo-
nents in these nonacute occlusions.1,2 This clot component
was implicated as a source of embolization after plain
angioplasties3 or postoperative occlusions,4 and a number
of interventions other than the time-consuming thrombol-
ysis, including enclosed thrombolysis,4,5 and mechanical
thrombectomy using various devices6 were used to address
this issue. Although effective in removing acutely formed
clots, the mechanical thrombectomy devices such as aspira-
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doi:10.1016/j.jvs.2007.05.050tion catheters6 and mechanical thrombectomy catheters are
considered to be unsuitable for removing subacute occlu-
sions of more than 14 days’ duration, because of the rapid
organization and adherence of the clot to the arterial
wall.7,8 A newer rotational catheter was proposed as a
means of effectively removing organized clots in a group of
patients with femoropopliteal occlusions.7
Patients presenting with subacute or chronic limb isch-
emia and total popliteal artery occlusions (PAOs) with a
patent or minimally diseased superficial femoral artery
present a unique and challenging group and are recom-
mended9 to have surgical bypass by the Trans-Atlantic
Society Consensus II (TASC) recommendation 37. Al-
though there are numerous reports on endovascular treat-
ment of femoropopliteal lesions, there have been few re-
ports on the treatment of isolated popliteal lesions with
percutaneous transluminal angioplasty (PTA),10 PTA with
stenting (PTA/S),11 and excimer laser atherectomy.12,13
Incidentally, there are no specific recommendations for
subacute presentations in the TASC document.9
Rheolytic thrombectomy (Angiojet; Possis Medical
Inc, Minneapolis, Minn) with earlier versions of this device
in subacute (14-day) occlusions in various arterial beds
has previously been reported, with promising results.14
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balloon angioplasty and stenting of the proximal popliteal
artery in a medically high-risk patient who presented with a
2-month history of rest pain and a total PAO after a rapid,
unrestricted, nonspiraling traversal of the occlusion with a
Glidewire (Terumo, Somerset, NJ), we started to favor this
approach in this subgroup of patients. The purpose of our
study was to describe our periprocedural and mid-term
results with this approach in patients with subacute isolated
PAO and to describe our technique.
MATERIALS AND METHODS
This was a retrospective analysis of a prospectively
maintained database that included information from all
patients who had isolated PAOs between February 2004
and January 2007 and who underwent primary rheolytic
thrombectomy with the Angiojet device followed by
PTA/S in the VA Western New York Healthcare System
(Buffalo, NY). Patients with popliteal artery aneurysms and
chronic occlusions in whom rheolytic thrombectomy was
not attempted were not included. The patients’ demo-
graphics, comorbidities, clinical presentation (Rutherford
classification),15 duration of symptoms (with emphasis on
the time of acute worsening of symptoms), noninvasive
arterial studies (ankle-brachial index; ABI), length and
location (P1, P2, or P3)11 of occlusions and stenoses before
and after rheolytic thrombectomy, number of runoff vessels
as determined by runoff scores,15 details of the procedures
performed, total stented vessel length, postoperative
course, length of stay, follow-up noninvasive arterial stud-
Fig 1. A 58-year-old smoker with chronic myeloid
presented with left foot rest pain for 8 weeks and a s
ankle-brachial index of 0.3. An angiogram shows the tota
XPeedior catheter shows visualization of all infrapoplitea
artery, in addition to the stenosis at the P1 segment (b).
artery and balloon angioplasty of the proximal anterior ties, and condition of the limbs and patients were recorded.All endovascular procedures were performed by vascu-
lar surgeons in the operating room by using the OEC 9800
system (GE Medical Systems, Salt Lake City, Utah). All
interventions but one were performed via the contralateral
femoral artery approach using a 6F sheath (Figs 1, a, and 2,
a). All lesions were easily crossed intraluminally by using a
combination of a Glidewire (0.035 inch, straight-tipped)
and a Glidecath (4F or 5F, angled; Terumo); distal intralu-
minal location was verified with dye injection, and a 0.018
inch guidewire (SV-5; Cordis, Johnson & Johnson, Miami,
Fla) was placed into a distal artery. An Angiojet XPeedior
catheter (120 cm; Angiojet, Possis Medical Inc., Minneap-
olis, Minn) was used alone in the first seven cases; however,
after the availability of the Angiojet DVX catheter (90 cm),
this catheter was used primarily, if it reached the lesion, as
judged by the catheter used for crossing the lesions. When
the DVX did not cross the occlusion because of inadequate
length, an XPeedior catheter either was used alone or was
used to clear the distal part of the occlusion before PTA/S
proceeded. Additional ipsilateral access was not obtained to
use the DVX catheter from the contralateral side in any
case.
If the occlusion extended to the infrapopliteal vessels, a
smaller catheter (Angiojet XMI) was used. The catheters
were passed at 2 to 3 mm/s through the occlusion twice,
starting proximally, and the angiogram was repeated to
assess the result after thrombectomy (Figs 1, b, and 2, b).
Although not routinely timed, the setting up of the Angio-
jet device and completion of the thrombectomy added
approximately 20 to 30 minutes to the procedure in our
mia (in remission), hypertension, and hyperlipidemia
area of gangrene at the tip of the great toe, with an
liteal artery (a). The angiogram after two passages of the
ls with significant stenosis at the proximal anterior tibial
nal result is shown after stent placement in the popliteal
artery (c).leuke
mall
l pop
l vesse
The fihands. A 4-mm (Savvy; Cordis, Johnson & Johnson) bal-
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2 minutes to dilate the popliteal artery, with the intention
of having a more stable plaque after dilation.16 The angio-
gram was repeated, and a self-expanding nitinol stent
(Smart or Precise; Cordis, Johnson & Johnson) was used
when there was a suboptimal result with an intimal flap,
persistent irregularity of the wall, or residual stenosis
greater than 20%. The size of the stent and postdilation
balloon diameter were estimated by comparing the target
size to the 4-mm predilation balloon. The most commonly
used stent diameters were 5 and 6 mm. In-stent balloon
dilation was always performed with a 4- or 5-mm balloon,
avoiding the stent edges. Additional balloon dilations
(2.5-3 mm; Savvy) were performed if significant stenosis
was seen in the infrapopliteal arteries to improve runoff (Fig
1, b and c). The final angiogram (Figs 1, c, and 2, d)
included visualization of the infrapopliteal arteries to rule
out distal embolization. The total occlusion length, post–
rheolytic thrombectomy lesion length, and stent length
were measured after the procedure by referencing these
lengths to the known length of the balloon catheter mark-
ers.
Patients typically received 5000 U of heparin after
sheath placement, and the heparin was not reversed at the
end of the procedure. The sheaths used were removed by
using manual compression in the recovery room after acti-
vated clotting time was less than 180 seconds or in the
operating room by using a closure device after 2005 (Pro-
Glide, Starclose, or Perclose; Abbott Vascular Inc, Red-
wood City, Calif). Clopidogrel bisulfate 75 mg was started
before the planned procedure or was started in recovery
room (300 mg). All patients were kept on clopidogrel 75
mg and enteric-coated acetyl salicylic acid (ECASA) 81 mg
for a minimum of 6 weeks followed by lifelong ECASA.
Technical success was defined as a patent vessel with less
than 30% residual stenosis. All patients were followed up by
our vascular laboratory at 3 and 6 months and every 6
months thereafter for ABI measurements and duplex imag-
ing. Angiography was performed when duplex imaging
suggested greater than 50% restenosis or when clinically
indicated. We attempted to obtain magnified plain radio-
graphs in all 10 stented patients for the purposes of this
study but accomplished this only in 6, which included those
who presented and were treated by thrombolysis.
Results were reported by using the Society for Vascular
Surgery reporting standards for lower extremity arterial
endovascular procedures.15 Data analysis was performed
with SPSS 14.0 software (SPSS Inc, Chicago, Ill). Kaplan-
Meier analysis was used to report primary patency, second-
ary patency, and limb salvage.
RESULTS
A total of 16 patients (all male; mean age, 68.9  11.1
years; range, 54-84 years) were treated. This constituted
6.8% of the 234 infrainguinal reconstructions (bypass, en-
dovascular, and combined) and 39% of the 41 percutane-
ous popliteal interventions performed during this period.
The remaining isolated popliteal interventions during thisperiod included PTA (10 patients), PTA/S (4 patients),
excimer laser atherectomy (Spectranetics Corp, Colorado
Springs, Colo) with PTA (7 patients), and atherectomy (4
patients; Silverhawk; Foxhollow Technologies, Inc, Red-
wood City, Calif), for 19 stenoses and 6 occlusions of the
popliteal artery. An additional patient had a bypass proce-
dure after failure to cross his chronic popliteal occlusion.
The characteristics, comorbidities, and preoperative func-
tional status are shown in Table I. The presenting symptom
was disabling claudication (Rutherford 3) in only one pa-
tient, whereas the remaining 94% had critical limb ischemia
(Table I). The mean duration of symptoms was 10.6 7.4
weeks (range, 4-24 weeks). Four patients had symptom
duration between 12 and 24 weeks.
The mean occlusion length was 11.6  4.5 cm. After
rheolytic thrombectomy, the occlusions were converted to
long stenoses (mean length, 7.6  3.6 cm). The locations
of the occlusions (P1, P2, or P3) before and after rheolytic
thrombectomy are shown in Table II. The number of
involved anatomic segments decreased in 44% of the pa-
tients, and all lesions were converted to long stenoses from
occlusions. Balloon dilation was used in 6 patients (38%),
and self-expanding stents were used in the remaining 10
(mean length, 8.3  4.4 cm). The procedural success rate
was 100%. Additional recanalization of occlusions of the
iliac artery and proximal superficial femoral artery was per-
formed before popliteal artery recanalizations in two pa-
tients, both of whom had gangrene, and palpable pedal
pulses were achieved in both. Both patients had angio-
graphic evidence of these concomitant occlusions before
the intervention was initiated.
The number of runoff vessels was 1 in 38%, 2 in 38%, 3
in 19%, and 0 in 6% of patients, with a mean runoff score of
Table I. Baseline characteristics
Variable Data
Age, y, mean  SD (range) 68.9  11.1 (54-84)
Male 100%
Presenting clinical category
Disabling claudication (Rutherford 3) 6%
Rest pain (Rutherford 4) 31%
Nonhealing ulcer (Rutherford 5) 13%
Gangrene 50%
Rutherford 5 (minor tissue loss) 31%
Rutherford 6 (major tissue loss) 19%
Comorbidities
Hypertension 69%
Diabetes 31%
Coronary artery disease 50%
Hyperlipidemia 75%
Pulmonary disease 13%
Cerebrovascular accident 12%
Creatinine 1.5 mg/dL 6%
Smoking history 94%
Active smokers 56%
Nonambulatory 25%
ASA class III or IV 88%
ASA, American Society of Anesthesiologists.1.7 0.9. The ABI increased from 0.27 0.22 before the
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distal embolization was observed, as determined by com-
pletion angiogram and clinical assessment. Adjuvant
thrombolysis was used for 16 hours in one case with ante-
rior tibial runoff to see if additional infrapopliteal vessels
could be visualized for recanalization (Fig 2, a and b), and
anterior tibial and tibioperoneal artery balloon angioplas-
ties were performed the following day, thus resulting in
three-vessel runoff (Fig 2, c and d). Inline flow to the foot
was achieved in all patients except one patient with forefoot
gangrene, who later underwent a popliteal-posterior tibial
bypass at the malleolar level using the great saphenous vein
to heal his open transmetatarsal amputation site. Because of
a limited length of useable great saphenous vein, his prox-
imal anastomosis had to be performed at the previously
recanalized distal popliteal artery.
The mean length of stay was 6.7  10.8 days (range,
1-40 days; median, 2 days), with 31% discharged in 1 day
and 75% discharged in 3 days. The length of stay was mainly
dictated by the wound care–related and placement issues.
There were no early postoperative complications. Eight of
10 patients with tissue loss had complete healing of their
wounds in 3.1 1.7 months (range, 1-6 months) after the
intervention. The remaining two, both diabetics (one had a
large heel gangrene, and the other was homeless and had
poor hygiene) who had incompletely healed wounds, un-
derwent below-knee amputations due to foot sepsis 7 and 9
months later with patent popliteal arteries. The bedridden
patient with dementia who had heel gangrene developed
contralateral heel gangrene and died of postoperative myo-
cardial infarction after contralateral amputation 12 months
after the initial procedure. This patient constitutes the only
long-term mortality so far in this series.
One-year primary and secondary patency rates were
84% 10% and 92% 8% by Kaplan-Meier analysis. Three
occlusions occurred at 3, 6, and 20 months after surgery
(mean follow-up, 15.7  10.0 months); all of these pa-
tients had initial stent placements, and two underwent
successful thrombolysis followed by additional stent place-
ments to the proximal and distal ends of the previously
placed stents. These have remained patent 22 and 36
months after the initial procedure, with patients then main-
tained on lifelong clopidogrel in addition to ECASA. Their
Table II. Location of the popliteal artery lesions before
and after Angiojet thrombectomy
Location Before Angiojet After Angiojet
P1 2 5
P2 1 3
P3 3 4
P1 and P2 1 1
P2 and P3 6 2
P1, P2, and P3 3 1
P1, First portion of the popliteal artery between the Hunter canal and
popliteal fossa; P2, end of P1 to the knee joint; P3, from the knee joint to the
takeoff of the anterior tibial artery.10original angiograms were re-reviewed, and we found noindication of a missed lesion or a suboptimal result. The
third patient whose popliteal artery reoccluded in 3 months
refused further intervention and remains a claudicant.
There were no significant (50%) restenoses found during
duplex follow-up in the remaining patients. Two limb
losses occurred at 7 and 9 months because of recurrent foot
infection in patients with diabetes, both with patent popli-
teal arteries, thus giving an overall limb salvage rate of 88%.
The only patient who was lost to our follow-up was the one
who refused further treatment of his occluded popliteal
artery.
We obtained magnified x-ray imaging 3 to 20 months
after the procedure in 6 of the 10 patients who had stent
placements and could not identify any stent fractures. This
included the two patients who had late occlusions.
DISCUSSION
Presentation more or less than 2 weeks after a sudden
decrease in arterial flow to the limb is usually the cutoff
between acute and nonacute limb ischemia, and presenta-
tions between 2 weeks and 3 months are usually considered
to be subacute and more than 3 months as chronic.1,2,7,9
Although the timing of presentation may affect the com-
position of the occluded vessel, with more likelihood of
harboring organizing clot in the subacute7 than chronic
setting, there are no specific recommendations for this
subgroup of patients. The cutoff of 3 months between
subacute and chronic in most studies is arbitrary at best,
and some occlusions of greater than 3 months may contain
a significant clot load, as was seen in four patients in our
series. The presence of varying degrees of clot in subacute
and chronic occlusions was confirmed by Wholey et al,1
who reported complete thrombolysis in 77% of subacute
and 75% of chronic (3 months) occlusions after throm-
bolytic infusion, both of which were significantly lower
than the 86% achieved in acute cases.
Because of the high cost and risks involved with the
lengthy thrombolytic therapy, various methods have been
used to debulk the clot component of subacute and chronic
occlusions in various arterial beds, mainly with the inten-
tion of reducing the incidence of distal embolization after
an intervention.4-7,17,18 One of these modalities involved
proximal and distal balloon occlusion and enclosed throm-
bolysis4,5; however, even a recent modification of this de-
vice resulted in 11% distal embolization.18 Debris was
retrieved from the filters from all 10 patients who under-
went atherectomy using a newer-generation device in fem-
oropopliteal arteries.19 Although there are various throm-
bectomy devices, their effectiveness decreases as the age of
the clot increases, with more organization and adherence to
the arterial wall.20 Duc et al7 reported their results with a
newer device (8F; Straub Rotarex; Straub Medical, Wangs,
Switzerland) designed for removing organized thrombus in
a heterogenous group of acute (n 17) and subacute (n
24) femoropopliteal occlusions. Distal embolization was
observed in 24%, and vessel perforation was seen in 12% of
the cases, although none of these was of major conse-
quence, but there was 10% early reocclusion in this series.
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subacute occlusions in a variety of arterial beds by using the
Angiojet thrombectomy device with adjunctive thrombol-
ysis and found the results to be similar between groups.
Because the widely available Angiojet thrombectomy
device was not originally designed for removing organized
clot, a newer catheter (DVX) with five times the suctioning
power was designed in response to the growing need for
removing organized clot. However, the DVX catheter was
made available only in the 90-cm length, and this made it
impossible to treat some of the popliteal occlusions in our
series, because we usually had access from the contralateral
femoral artery. Although the DVX device was more effec-
tive in removing organized clots, we used the XPeedior
catheter in some cases with good results. We have not
encountered any cases of distal embolization, perforation,
or early reocclusion in any of our patients.
Popliteal occlusions are classified as TASC D lesions,
and the recommended treatment is surgical bypass.9 There
have been several reports on short-segment bypasses using
vein grafts, with 82% to 86% 1-year and 55% to 75% 5-year
primary patency, associated with 0% to 5.2% 30-day mor-
tality and 0-9.6% 30-day occlusion rates.21-25 However,
because of the associated comorbidities, unavailability of
adequate veins, and minimal invasiveness, endovascular
interventions are increasingly used in these patients. Still,
most reports bundle these lesions with femoral interven-
tions, and few reports focus only on popliteal arteries.10-12
The TASC document does not specifically differentiate
between chronic and subacute presentations, and the treat-
ment recommendations are based on the length of stenoses/
occlusions of each anatomic segment being considered for
Fig 2. A 54-year-old smoker with hypertension, hyper
(ankle-brachial index, 0.1). The angiogram shows total o
After Angiojet thrombectomy, the angiogram shows sig
anterior tibial artery (b). Overnight thrombolysis result
patent posterior tibial and peroneal arteries (c). The final
tibioperoneal arteries is shown (d).treatment. Because the subacute occlusions are all consid-ered to be nonacute—hence “chronic”—the long occlu-
sions of the popliteal artery are considered to be TASC D
lesions, and bypass is the recommended treatment. The
occluded segments may contain varying degrees of clot
component, the removal of which may result in a newer
anatomic configuration (converting into varying degrees of
stenoses), thus downgrading the TASC classification into
A, B, or C. This results in a whole different treatment
recommendation after clot removal. Because the likelihood
of a clot component is increased by the timing of presenta-
tion (acute vs subacute vs chronic), as well as the manner
with which the Glidewire crosses these lesions, we think
that the TASC document needs to be revised to address this
issue. Although there are a number of retrospective studies
on the treatment of subacute occlusions,1,2,4-7,14,20,26,27
well-conducted prospective studies are needed to address
this problem.
The patients with PAOs treated in this study are unique
in several aspects. First, they are not rare and constituted
39% of all our patients who underwent percutaneous pop-
liteal interventions. The percentage of patients with diabe-
tes was less than expected (31% vs 56% in our patients with
chronic limb ischemia; P  .073), as was that with renal
insufficiency (6% vs 26%; P .084), whereas active smokers
were more numerous (56% vs 41% in our chronic limb
ischemia population; P  .304). However, because of the
small sample size, the differences did not reach statistical
significance. Although this may suggest that hypercoagula-
bility and plaque rupture play a role in the unique presen-
tation in our patients, this was not supported by our small
series. Most of our patients had a subacute presentation
with a clear worsening of symptoms within 1 to 3 months
mia, and a 20-week history of rest pain in the left foot
on of the P2 and P3 segments of the popliteal artery (a).
nt stenosis at the P2 popliteal artery and the proximal
visualization of the proximal tibioperoneal artery with
gram after balloon angioplasties of the anterior tibial andlipide
cclusi
nifica
ed in
angio(four presented within 3-6 months) and could be treated
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their lesions to long stenoses enabled some of them to be
treated with balloon angioplasty alone, but most still
needed a stent for an acceptable technical result. Our
experience parallels that of Strecker et al11 in that we did
not see any stent fractures or significant restenoses in this
group, although the follow-up is relatively short.
Although we had to use adjuvant thrombolysis in only
one patient, we think that it may play a role in selected
patients when the runoff status can be potentially increased
by an overnight thrombolysis. This happened in one of our
patients, and the runoff status was improved from one- to
three-vessel runoff with the additional recanalization of the
tibioperoneal artery the following day. Although we did
not observe any distal embolization in our series, this is still
a possibility, and one should be prepared to proceed with
postprocedural thrombolysis when this occurs.
The need for pretreatment rheolytic thrombectomy is
suggested by the clinical presentation (relatively clear mem-
ory of the worsening of symptoms in a patient with chron-
ically less severe disease, palpable ipsilateral femoral artery,
and a less diseased contralateral extremity with either pal-
pable pedal arteries or a significantly higher ABI) and the
ease and rapidity of intraluminal crossing of the long pop-
liteal occlusions. The usual experience involves minimal
difficulty in crossing the proximal diseased part, after which
the Glidewire “races” through the occlusion to the distal
patent vessel. If the occlusion is clearly chronic, heavily
calcified, and the Glidewire takes a subintimal course, there
is no role for the above-described technique, and the rou-
tine intervention of choice can be performed.
We have used intravascular ultrasonography to deter-
mine the need and location for a stent in some cases and
found this to be a useful adjunct; however, we cannot make
firm recommendations for its use before further experience.
Unfortunately, we did not make any observations regard-
ing plaque rupture or any plaque analysis in patients for
whom we used the intravascular ultrasonography, and
therefore we cannot comment on these matters. We used
stents in 10 of our 16 patients because of suboptimal results
after PTA; however, this is still lower than our routine use
of stents in TASC C and D superficial femoral artery lesions.
The advantages of our approach in this group of pa-
tients are its minimal invasiveness, rapidity of the treatment
of an otherwise complex lesion, minimal complications,
and reasonable long-term outcomes. It is widely available
and seems to be safe. It requires a 6F sheath, which is the
usual sheath used in these interventions. The availability of
longer DVX catheters (120 cm) would increase the efficacy
of this intervention in this anatomic location.
The weaknesses of our study include its lacking a con-
trol group (endovascular intervention without rheolytic
thrombectomy, or surgical bypass) for comparison, in-
volvement of only male patients, not having used a filter or
means other than angiography for ruling out embolization,
and lack of long-term follow-up. In addition, because the
treatment was initiated after the actual crossing of the wire,
there was no intent to treat at the beginning of the inter-vention, and we cannot comment on the failure rate of our
approach to these lesions. Finally, we cannot comment on
the cost-effectiveness of our study, because we did not
make any cost estimations for the added operating room
time and device costs.
In conclusion, we have found that in a selected group of
patients with subacute limb ischemia, in whom a popliteal
occlusion is encountered and easily crossed intraluminally,
pre-emptive debulking of the organized clot component by
using rheolytic thrombectomy with an Angiojet, followed
by angioplasty with or without stenting, is a safe and
effective procedure with reasonable early and mid-term
results. The lack of distal embolization, a rare need for
adjunctive thrombolysis, ease of use, and availability made
this our preferred approach in this group of patients. The
validity of our observations needs to be confirmed in larger
prospective studies.
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